Article
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas.
Nature communications - 28 Apr 2020
Krishnan Aswini, Berthelet Jean, Renaud Emilie, Rosigkeit Sebastian, Distler Ute, Stawiski Eric, Wang Jing, Modrusan Zora, Fiedler Marc, Bienz Mariann, Tenzer Stefan, Schad Arno, Roth Wilfried, Thiede Bernd, Seshagiri Somasekar, Musholt Thomas J, Rajalingam Krishnaraj
Abstract excerpt
Papillary thyroid cancer (PTC) is the most common type of endocrine malignancy. By RNA-seq analysis, we identify a RET rearrangement in the tumour material of a patient who does not harbour any known RAS or BRAF mutations. This new gene fusion involves exons 1-4 from the 5' end of the Trk fused Gene (TFG) fused to the 3' end of RET tyrosine kinase leading to a TFG-RET fusion which transforms immortalized human...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.